Načítá se...
A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma
Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy and improved outcomes for patients with advanced disease. Pembrolizumab, a monoclonal antibody that acts as a programmed cell death 1 (PD-1(PDCD1)) inhibitor, has been approved for the treatment of advanced melanoma and other sol...
Uloženo v:
| Vydáno v: | Endocrinol Diabetes Metab Case Rep |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Bioscientifica Ltd
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6432978/ https://ncbi.nlm.nih.gov/pubmed/30836329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EDM-18-0153 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|